

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

29 Jun 2026

### Effect of probiotic supplementation for mother and for infant on bilirubin level and weight gain in very low birth weight infants: a three parallel arm randomized controlled trial

#### Protocol summary

##### Study aim

Effect of probiotic supplementation for mother and for infant on bilirubin level and weight gain in very low birth weight infants

##### Design

Randomized superiority placebo-controlled double blind trial with three parallel arms: 75 participants will be randomized into the groups by stratified block randomization using a computerized program.

##### Settings and conduct

In Al-Zahra and Taleghani teaching hospitals in Tabriz, eligible infants and their mothers will be studied after receiving informed written consent from the mothers and fathers. The participants, those recruiting participants and those collecting and analyzing data will be blinded.

##### Participants/Inclusion and exclusion criteria

Participants will be mothers and their infants with birth weight of 1000-1500 g. The mothers should have given birth in the past 48 h, have desire and ability to breastfeed, and be able to attend the hospital at least once a week. The infants should be hospitalized for at least 7 days after start of the intervention. Exclusion criteria include: Triplets or more, Infants' bad condition, contraindications to breastfeed, existence of obvious anomalies in the neonate, regular use of probiotics (in any form) by the mother, history of probiotic allergy or existence of immunity disorders in the mother, and unwillingness to participate in the study

##### Intervention groups

In all three groups, both mothers and their infants will take capsule of probiotic supplements or placebo, once a day for 28 days as following: Intervention 1: mothers will take probiotic and their infants will take placebo. Intervention 2: mothers will take placebo and their infants will probiotic. Control group: both mothers and their infants will take placebo.

##### Main outcome variables

Level of total serum bilirubin in the third and seventh days of intervention, and infant weight gain during 28 days of intervention.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20100414003706N38**

Registration date: **2021-01-24, 1399/11/05**

Registration timing: **prospective**

Last update: **2021-01-24, 1399/11/05**

Update count: **0**

##### Registration date

2021-01-24, 1399/11/05

##### Registrant information

##### Name

Sakineh Mohammad-Alizadeh-Charandabi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 3477 2699

##### Email address

alizades@tbzmed.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-02-19, 1399/12/01

##### Expected recruitment end date

2021-07-23, 1400/05/01

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Effect of probiotic supplementation for mother and for infant on bilirubin level and weight gain in very low birth weight infants: a three parallel arm randomized controlled trial

**Public title**

Probiotic supplementation for mother and for very low birth weight infants

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

Delivery in the past 48 h  
Desire and ability to breastfeed her baby  
Neonatal birth weight of 1000 to 1500 g  
Hospitalization of the infant for at least 7 days after the start of the intervention  
Possibility of the mother to attend hospital where the baby is admitted, at least once a week

**Exclusion criteria:**

Triplets or more  
Infant bad condition diagnosed by a neonatologist.  
Contraindications to breastfeed  
Existence of obvious anomalies in the neonate  
Regular use of probiotics (in any form) by the mother  
History of probiotic allergy in the mother  
Immunodeficiency in the mother  
Unwillingness to participate in the study

**Age**

From **18 years** old to **45 years** old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **75**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Participants will be individually randomized into interventions or control groups using stratified (single or twin pregnancy and the two recruitment center) block randomization with block size of three. Allocation sequence will be determined using a computerized program. Probiotic supplements or placebos will be prepared in sequentially numbered packages based on the allocation sequence.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Probiotic supplements and placebo will be prepared in identical shape, color, smell and packages. The sequence

generation and preparation of the packs will be done by a person not involved in participant recruitment or data collection. In the group with probiotic administration to the infant, probiotic placebo will be prescribed to the mother; in the group with probiotic administration to the mother, probiotic placebo will be prescribed to the infant; and in the control group, both mother and infant will be given probiotic placebo. The investigators, health care providers, outcome assessors, and statistical analyst will be blinded.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Tabriz University of Medical Sciences

**Street address**

No. 2 Central Building, Tabriz University of Medical Sciences, Golgasht Ave., Tabriz, Iran

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Approval date**

2021-01-18, 1399/10/29

**Ethics committee reference number**

IR.TBZMED.REC.1399.948

**Health conditions studied****1****Description of health condition studied**

Hyperbilirubinemia (Jaundice)

**ICD-10 code**

P59.9

**ICD-10 code description**

Neonatal jaundice, unspecified

**2****Description of health condition studied**

Mastitis

**ICD-10 code**

O91.22

**ICD-10 code description**

Nonpurulent mastitis associated with the puerperium

### 3

#### **Description of health condition studied**

Very low birth weight

#### **ICD-10 code**

P07.10

#### **ICD-10 code description**

Other low birth weight newborn, unspecified weight

## **Primary outcomes**

### 1

#### **Description**

Total serum bilirubin level

#### **Timepoint**

The third and seventh days of intervention

#### **Method of measurement**

laboratory assessment

### 2

#### **Description**

Weight gain during neonatal period

#### **Timepoint**

At baseline, 7th day of intervention and 28th days after birth

#### **Method of measurement**

Using a digital scale

## **Secondary outcomes**

### 1

#### **Description**

Total duration of phototherapy (hours)

#### **Timepoint**

During neonatal period

#### **Method of measurement**

Daily assessment of infant medical record

### 2

#### **Description**

Length of total parenteral nutrition

#### **Timepoint**

Daily assessment during hospital stay of the infant

#### **Method of measurement**

Daily assessment of infant medical record

### 3

#### **Description**

Infant age at full enteral feeding (day)

#### **Timepoint**

Daily assessment during hospital stay of the infant

#### **Method of measurement**

Daily assessment of infant medical record

### 4

#### **Description**

Composite variable of occurrence of serious neonatal

problems (including Bronchopulmonary dysplasia, sepsis, Necrotizing enterocolitis, or Retinopathy of prematurity)

#### **Timepoint**

Until about 40 days of infancy

#### **Method of measurement**

Diagnosed by neonatologist and ophthalmologist based on clinical and para-clinical assessments (Retinopathy of prematurity will be assessed by an ophthalmologist after 28 days of infancy)

### 5

#### **Description**

Duration of infant hospitalization

#### **Timepoint**

Until discharge from hospital (if discharged earlier than 28 days, assessment after 28 days for re-admission to hospital)

#### **Method of measurement**

Assessment of infant medical record and contact with the mother after 28 days in case of early discharge

### 6

#### **Description**

Occurrence of mastitis in the mother

#### **Timepoint**

During 28 days of childbirth

#### **Method of measurement**

At least weekly assessment using the Mastitis scale

## **Intervention groups**

### 1

#### **Description**

Intervention group 1: One capsule of probiotic supplement containing  $1.5 \times 10^9$  CFU of Lactobacillus Paracasei (subspecies Paracasei) will be given daily to the mother and one placebo capsule (similar to the probiotic capsule containing starch powder, dissolved in her mother's breast-milk) daily to her infant for 28 days .

#### **Category**

Prevention

### 2

#### **Description**

Intervention group 2: One placebo capsule similar to a probiotic capsule containing starch powder will be given daily to the mother and one capsule of probiotic containing  $1.5 \times 10^9$  CFU of Lactobacillus Paracasei (subspecies Paracasei, dissolved in her mother's breast-milk) daily to her infant for 28 days .

#### **Category**

Prevention

### 3

#### **Description**

Control group: Both mothers and their infants will receive placebo capsules once a day for 28 days.

#### **Category**

Prevention

## Recruitment centers

### 1

#### Recruitment center

**Name of recruitment center**

Taleghani hospital

**Full name of responsible person**

Dr Behzad Sarvaran Mehran

**Street address**

Rah-Ahan Square, Tabriz

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5183617845

**Phone**

+98 41 3442 4421

**Email**

taleghani.hosp@tbzmed.ac.ir

**Web page address**

<https://taleghanihosp.tbzmed.ac.ir/?PageID=0>

### 2

#### Recruitment center

**Name of recruitment center**

Al-Zahra hospital

**Full name of responsible person**

Dr Maryam Vaezie

**Street address**

Bage-Shomal Intersection, South Artesh Ave., Tabriz

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138663134

**Phone**

+98 41 3553 9161

**Email**

alzahra@tbzmed.ac.ir

**Web page address**

<https://alzahrahosp.tbzmed.ac.ir/>

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Dr. Mohammad Samiei

**Street address**

No. 2 Central building of the university, Golgasht street, Azadi street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Phone**

+98 41 3335 7310

**Email**

research-vice@tbzmed.ac.ir

**Web page address**

<https://researchvice.tbzmed.ac.ir/>

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tabriz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

## Person responsible for general inquiries

#### Contact

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Mahtab Matin

**Position**

MSc student in midwifery

**Latest degree**

Bachelor

**Other areas of specialty/work**

Midwifery

**Street address**

Nursing & Midwifery Faculty, South Shariati Ave., Tabriz

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

59691-15868

**Phone**

+98 44 4436 3557

**Email**

mahtab.matin43@gmail.com

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Sakineh Mohammad-Alizadeh-Charandabi

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Reproductive Health

**Street address**

Faculty of Nursing & Midwifery, South Shariati Ave.,  
Tabriz

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138947977

**Phone**

+98 41 3479 6969

**Email**

alizades@tbzmed.ac.ir

**Web page address**

[https://isid.research.ac.ir/Sakineh\\_MohammadAlizadeh](https://isid.research.ac.ir/Sakineh_MohammadAlizadeh)

**Email**

mhammadalizadehs@gmail.com

**Web page address**

[https://isid.research.ac.ir/Sakineh\\_MohammadAlizadeh](https://isid.research.ac.ir/Sakineh_MohammadAlizadeh)

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Requested data will be provided to researchers for statistical analysis (meta- analysis) of the submitted proposal.

**When the data will become available and for how long**

starting immediately after publication of the study results

**To whom data/document is available**

Data will be available to researchers working at academic organizations, as well as to chief editor (and reviewers) of the journal of the submitted manuscript/s, if requested.

**Under which criteria data/document could be used**

The data will be available to researchers upon request and submission of a proposal to perform meta-analysis using IPD data after being unidentified. Also, in exceptional cases, data will be made available to journal of submitted manuscript/s for checking accuracy of the data

**From where data/document is obtainable**

Refer to the email address (alizades@tbzmed.ac.ir; mhammadalizadehs@gmail.com)

**What processes are involved for a request to access data/document**

The requests will be sent by email and data will be available within a week.

**Comments****Person responsible for updating data****Contact****Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Sakineh Mohammad-Alizadeh-Charandabi

**Position**

Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Reproductive Health

**Street address**

Faculty of Nursing & Midwifery, South Shariati Street,  
Tabriz

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5138947977

**Phone**

+98 41 3479 6969